Your browser doesn't support javascript.
loading
The Effects of Trimetazidine on QT-interval Prolongation and Cardiac Hypertrophy in Diabetic Rats / Os Efeitos da Trimetazidina no Prolongamento do Intervalo QT e na Hipertrofia Cardíaca em Ratos Diabéticos
Ramezani-Aliakbari, Fatemeh; Badavi, Mohammad; Dianat, Mahin; Mard, Seyed Ali; Ahangarpour, Akram.
  • Ramezani-Aliakbari, Fatemeh; Ahvaz Jundishapur University of Medical Sciences. Faculty of Medicine. Physiology Research Center. Ahvaz. IR
  • Badavi, Mohammad; Ahvaz Jundishapur University of Medical Sciences. Faculty of Medicine. Physiology Research Center. Ahvaz. IR
  • Dianat, Mahin; Ahvaz Jundishapur University of Medical Sciences. Faculty of Medicine. Physiology Research Center. Ahvaz. IR
  • Mard, Seyed Ali; Ahvaz Jundishapur University of Medical Sciences. Faculty of Medicine. Physiology Research Center. Ahvaz. IR
  • Ahangarpour, Akram; Ahvaz Jundishapur University of Medical Sciences. Faculty of Medicine. Physiology Research Center. Ahvaz. IR
Arq. bras. cardiol ; 112(2): 173-178, Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-983835
ABSTRACT
Abstract

Background:

Trimetazidine (TMZ) is an anti-ischemic drug. In spite of its protective effects on cardiovascular system, there is no scientific study on the usefulness of TMZ treatment for prolonged QT interval and cardiac hypertrophy induced by diabetes.

Objectives:

To evaluate the effects of TMZ on QT interval prolongation and cardiac hypertrophy in the diabetic rats.

Methods:

Twenty-four male Sprague-Dawley rats (200-250 g) were randomly assigned into three groups (n = 8) by simple random sampling method. Control (C), diabetic (D), and diabetic administrated with TMZ at 10 mg/kg (T10). TMZ was administrated for 8 weeks. The echocardiogram was recorded before isolating the hearts and transfer to a Langendorff apparatus. Hemodynamic parameters, QT and corrected QT interval (QTc) intervals, heart rate and antioxidant enzymes were measured. The hypertrophy index was calculated. The results were evaluated by one-way ANOVA and paired t-test using SPSS (version 16) and p < 0.05 was regarded as significant.

Results:

The diabetic rats significantly indicated increased hypertrophy, QT and QTc intervals and decreased Left ventricular systolic pressure (LVSP), Left ventricular developed pressure (LVDP), rate pressure product (RPP), Max dp/dt, and min dp/dt (±dp/dt max), heart rate, superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase in the heart. Treatment with TMZ in the diabetic animals was significantly improved these parameters in comparison to the untreated diabetic group.

Conclusions:

TMZ improves QTc interval prolongation and cardiac hypertrophy in diabetes.
RESUMO
Resumo Fundamento A trimetazidina (TMZ) é uma droga anti-isquêmica. Apesar de seus efeitos protetores sobre o sistema cardiovascular, não há estudos científicos sobre a utilidade do tratamento com TMZ para o intervalo QT prolongado e a hipertrofia cardíaca induzida pelo diabetes.

Objetivo:

Avaliar os efeitos da TMZ no prolongamento do intervalo QT e na hipertrofia cardíaca em ratos diabéticos.

Métodos:

Vinte e quatro ratos machos Sprague-Dawley (200-250 g) foram distribuídos aleatoriamente em três grupos (n = 8) pelo método de amostragem aleatória simples. Controle (C), diabético (D) e diabético administrado com TMZ a 10 mg/kg (T10). A TMZ foi administrada por 8 semanas. O ecocardiograma foi registrado antes de isolar os corações e transferir para um aparelho de Langendorff. Foram medidos os parâmetros hemodinâmicos, intervalo QT e intervalo QT corrigido (QTc), frequência cardíaca e enzimas antioxidantes. O índice de hipertrofia foi calculado. Os resultados foram avaliados pelo one-way ANOVA e pelo teste t pareado pelo SPSS (versão 16) e p < 0,05 foi considerado significativo.

Resultados:

Os ratos diabéticos indicaram hipertrofia aumentada, intervalos QT e QTc e diminuição da pressão sistólica no ventrículo esquerdo (PSVE), pressão desenvolvida no ventrículo esquerdo (PDVE), duplo produto (DP), Max dp/dt e min dp/dt (± dp/dt max), frequência cardíaca, superóxido dismutase (SOD), glutationa peroxidase (GPx) e catalase no coração. O tratamento com TMZ nos animais diabéticos melhorou significativamente esses parâmetros em comparação com o grupo diabético não tratado.

Conclusões:

A TMZ melhora o prolongamento do intervalo QTc e a hipertrofia cardíaca no diabetes.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Trimetazidine / Long QT Syndrome / Cardiomegaly / Protective Agents / Diabetes Complications Type of study: Etiology study / Evaluation studies Limits: Animals Language: English Journal: Arq. bras. cardiol Journal subject: Cardiology Year: 2019 Type: Article Affiliation country: Iran Institution/Affiliation country: Ahvaz Jundishapur University of Medical Sciences/IR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Trimetazidine / Long QT Syndrome / Cardiomegaly / Protective Agents / Diabetes Complications Type of study: Etiology study / Evaluation studies Limits: Animals Language: English Journal: Arq. bras. cardiol Journal subject: Cardiology Year: 2019 Type: Article Affiliation country: Iran Institution/Affiliation country: Ahvaz Jundishapur University of Medical Sciences/IR